News
Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France
PRESS RELEASE Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement for France. Hørsholm, Denmark January 13th 2025 - AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing...
Er-Kim and AFYX Therapeutics A/S announce distribution and sales collaboration
PRESS RELEASE Hørsholm, Denmark – 6th January 2025 Er-Kim and AFYX Therapeutics A/S announced today a distribution and sales collaboration for two AFYX products. The two companies have entered a mutual sales and distribution collaboration where Er-Kim will sell and...
Danish biopharmaceutical leader AFYX Therapeutics A/S secures DKK 25 million in Funding
Danish Biopharmaceutical Leader AFYX Therapeutics A/S Secures DKK 25 million in Funding to Drive Product Development and Global Expansion. PRESS RELEASE Copenhagen, Denmark – December 19, 2025 AFYX Therapeutics A/S, a pioneering Danish biopharmaceutical company...
OUR LATEST INVESTOR PRESENTATION
Download here:
AFYX THERAPEUTICS HQ
Slotsmarken 11, 1.tv.
DK-2970 Hørsholm
Denmark
VAT: 38793594
Phone: +45 7174 7174
info@afyxtx.com
AFYX NORWAY
Gaustadalléen 21
NO-0349 Oslo
Norway
VAT: 922 558 221
Phone: +47 2396 7174
